ALK and neuroblastoma: These findings provide evidence to support additional evaluations of lorlatinib combinations with the SHP2 inhibitor TNO155, which is currently in phase I/II trials for adult cancers, for the treatment of relapsed ALK-mutant neuroblastoma, including those with acquired resistance to ALK inhibitors.